M&A, new modalities, and COVID-19 have all changed the way drug sponsors work with their third-party manufacturers, according to delegates from Samsung Biologics, Catalent, and AGC Biologics.

The BioProcess Insider Expression Platform (BIEP) podcast is back, with an in-depth look at the evolving relationships between biopharma and their contract development and manufacturing organization (CDMO) partners.

Recorded live from EBD’s BIO Europe Spring event last month, BioProcess Insider discussed the changing dynamic and reliance drug sponsors have with their CDMOs with:

• Kevin Sharp, VP, Head of Global Sales Strategic Operations, Samsung Biologics
• Barbara Sambuco, VP Operations, Drug Product, Biotherapeutics, Catalent
• Christoph Winterhalter, SVP, Business Development, AGC Biologics

You can listen to the full panel via Spotify, Apple iTunes, Google Podcasts, and other platforms, or listen directly below: